Review: Neutralizing antibodies against interferon-beta
The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-β). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in...
| Κύριος συγγραφέας: | |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
SAGE Publishing
2008-09-01
|
| Σειρά: | Therapeutic Advances in Neurological Disorders |
| Διαθέσιμο Online: | https://doi.org/10.1177/1756285608095144 |